Tonix Pharmaceuticals (NASDAQ:TNXP) issued its quarterly earnings results on Monday. The company reported ($6.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($3.66) by ($2.44), MarketWatch Earnings reports.
TNXP opened at $2.81 on Tuesday. Tonix Pharmaceuticals has a 1-year low of $1.70 and a 1-year high of $51.10. The company has a market capitalization of $4.30 million, a price-to-earnings ratio of -0.10 and a beta of 1.85.
COPYRIGHT VIOLATION NOTICE: “Tonix Pharmaceuticals (TNXP) Announces Earnings Results, Misses Estimates By $2.44 EPS” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2019/03/19/tonix-pharmaceuticals-tnxp-announces-earnings-results-misses-estimates-by-2-44-eps.html.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
Recommended Story: Why Net Income is Important to Investors
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.